» Articles » PMID: 28089729

Urinary Biomarkers in Women with Refractory Urgency Urinary Incontinence Randomized to Sacral Neuromodulation Versus OnabotulinumtoxinA Compared to Controls

Overview
Journal J Urol
Publisher Wolters Kluwer
Specialty Urology
Date 2017 Jan 17
PMID 28089729
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: We measured urinary biomarker levels in women with refractory urgency urinary incontinence and controls at baseline and 6 months after treatment with sacral neuromodulation or intradetrusor injection of onabotulinumtoxinA. We also assessed the association of baseline biomarkers with posttreatment urgency urinary incontinence episodes and overactive bladder symptom bother outcomes.

Materials And Methods: First morning urine samples were collected from consented trial participants and age matched women without urgency urinary incontinence. Biomarkers reflecting general inflammation, neuroinflammation, afferent neurotransmitters and tissue remodeling were measured using standardized enzyme-linked immunosorbent assay and activity assays as appropriate. Symptom bother was assessed by the overactive bladder questionnaire and urgency urinary incontinence episodes were determined by bladder diary. Linear models were used to examine differences in mean biomarker levels and the change in urgency urinary incontinence episodes and symptom bother between baseline and 6 months. Modest evidence of a potential association was represented by p ≤0.01 and p ≤0.004 represented moderate evidence of an association with outcomes.

Results: Baseline biomarker levels differed little between cases and controls except tropoelastin (p = 0.001) and N-terminal telopeptide collagen type 1 (p <0.001). Changes in biomarker levels 6 months after intervention included decreases in collagenase (p <0.001) in both treatment groups and increases in interleukin-8 (p = 0.002) and matrix metalloprotease-9 (p <0.001) in the onabotulinumtoxinA group. Higher baseline calcitonin gene-related peptide across both treatments (p = 0.007) and nerve growth factor in the onabotulinumtoxinA arm (p = 0.007) were associated with less reduction in overactive bladder symptom bother.

Conclusions: Refractory urgency urinary incontinence is a complex condition. These data suggest that matrix remodeling and neuropeptide mediation may be involved in its pathophysiological mechanisms and response to treatment.

Citing Articles

The Pelvic Floor Disorders Network: Evolution Over Two Decades of Female Pelvic Floor Research.

Richter H, Visco A, Brubaker L, Sung V, Nygaard I, Arya L Urogynecology (Phila). 2025; 30(10):854-869.

PMID: 39752613 PMC: 11706353. DOI: 10.1097/SPV.0000000000001571.


Sacral Neuromodulation: Device Improvement and Current Applications in Urology.

Spilotros M, Gerbasi S, Lasorsa F, DE Rienzo G, Balducci L, Ditonno P Medicina (Kaunas). 2024; 60(3).

PMID: 38541235 PMC: 10972000. DOI: 10.3390/medicina60030509.


Feasibility of Real-Time Conditional Sacral Neuromodulation Using Wireless Bladder Pressure Sensor.

Majerus S, Offutt S, Brink T, Vasoli V, Mcadams I, Damaser M IEEE Trans Neural Syst Rehabil Eng. 2021; 29:2067-2075.

PMID: 34606460 PMC: 9359615. DOI: 10.1109/TNSRE.2021.3117518.


Genetic variants and expression changes in urgency urinary incontinence: A systematic review.

Post W, Ruiz-Zapata A, Grens H, De Vries R, Poelmans G, Coenen M Neurourol Urodyn. 2020; 39(8):2089-2110.

PMID: 32949220 PMC: 7692907. DOI: 10.1002/nau.24512.


Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses.

Siddiqui N, Helfand B, Andreev V, Kowalski J, Bradley M, Lai H J Urol. 2019; 202(5):880-889.

PMID: 30925127 PMC: 6766427. DOI: 10.1097/JU.0000000000000257.


References
1.
Liu H, Chancellor M, Kuo H . Urinary nerve growth factor level could be a biomarker in the differential diagnosis of mixed urinary incontinence in women. BJU Int. 2008; 102(10):1440-4. DOI: 10.1111/j.1464-410X.2008.07757.x. View

2.
Amundsen C, Richter H, Menefee S, Vasavada S, Rahn D, Kenton K . The Refractory Overactive Bladder: Sacral NEuromodulation vs. BoTulinum Toxin Assessment: ROSETTA trial. Contemp Clin Trials. 2014; 37(2):272-83. PMC: 3989885. DOI: 10.1016/j.cct.2014.01.009. View

3.
Liu H, Chen C, Kuo H . Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int. 2010; 107(5):799-803. DOI: 10.1111/j.1464-410X.2010.09585.x. View

4.
McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res Treat. 2006; 100(2):229-35. DOI: 10.1007/s10549-006-9242-8. View

5.
Amundsen C, Richter H, Menefee S, Komesu Y, Arya L, Gregory W . OnabotulinumtoxinA vs Sacral Neuromodulation on Refractory Urgency Urinary Incontinence in Women: A Randomized Clinical Trial. JAMA. 2016; 316(13):1366-1374. PMC: 5399419. DOI: 10.1001/jama.2016.14617. View